| MDL | MFCD02684280 |
|---|---|
| Molecular Weight | 499.60 |
| Molecular Formula | C26H37N5O5 |
| SMILES | O=C(N[C@@H](CC1=CC=C2C=CC=CC2=C1)C(N[C@@H](C)C(NCCN)=O)=O)[C@H](CC(C)C)CC(NO)=O |
TAPI-1 (1 µM for 30 min) increases cell viability in LPS-treated HK-2 cells
[1]
.
TAPI-1 attenuates oxidative stress and inflammatory cytokines
[1]
LPS treatment significantly induces renal IL-6 and TNFα mRNA expression, while these changes is attenuated with TAPI-1 pretreatment in LPS-treated HK-2 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | LPS-treated HK-2 cells |
| Concentration: | 1 µM |
| Incubation Time: | 30 minutes (pre-treated) |
| Result: | Increased cell viability. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : ≥ 31 mg/mL ( 62.05 mM )
* "≥" means soluble, but saturation unknown.
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0016 mL | 10.0080 mL | 20.0160 mL |
| 5 mM | 0.4003 mL | 2.0016 mL | 4.0032 mL |
| 10 mM | 0.2002 mL | 1.0008 mL | 2.0016 mL |